Trial Profile
STUDY TO EVALUATE BIOMARKERS OF SENSITIVITY AND RESISTANCE<BR>IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WHO<BR>ARE TREATED WITH BRENTUXIMAB VEDOTIN
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2014
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Biomarker
- 08 Aug 2014 New trial record